<DOC>
	<DOCNO>NCT02537470</DOCNO>
	<brief_summary>This dose-ranging study evaluate efficacy , safety tolerability range dose biphasic formulation remogliflozin etabonate compare placebo , administer 12 week subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>Safety Efficacy Biphasic Remogliflozin Etabonate Treatment Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Able provide write informed consent Subject clinical diagnosis type 2 diabetes HbA1c 7.0 10.5 % inclusive Visit 1 . History metabolic acidosis ketoacidosis . Current active renal disease relate hypertension type 2 diabetes ( e.g . nondiabetic glomerulonephritis , interstitial nephritis , symptomatic nephrolithiasis , etc . ) Use investigational device investigational drug within 30 day 5 halflives ( whichever longer ) prior Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>